Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TheraVac-03 NYVAC-B therapeutic HIV vaccine trial
NL-OMON31815Phase 2Withdrawn
- Sponsor
- EuroVacc Foundation
- Start
- Oct 2008
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing NYVAC-B + HAART with Placebo + HAART (2 arms). Planned start Oct 2008; status: withdrawn.
02
Drugs
NYVAC-B
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON31815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31815.